Xylazine
CAS: 7361-61-7 | Type: active_pharmaceutical
Moderate Risk (Adults)
Safety Summary
Hazard Profilehazardous
Risk (Adults)Moderate
Risk (Dogs)Low To Moderate
Risk (Cats)Moderate
Regulatory Status
SummaryNo major regulatory flags
Molecular FormulaC12H16N2S
Molecular Weight220.34
Sources
These citations are the ones recorded for the human adult context.
- US FDA: Xylazine — Veterinary Sedative Use, Alpha-2 Agonist Mechanism, Species Dose Differences, Cardiovascular Monitoring Requirements, Atipamezole Reversal, and 2023 Safety Alert Regarding Illicit Drug Supply Adulteration (2023) REGULATORY · 2023
- US CDC: Xylazine in the Illicit Drug Supply — Prevalence in Fentanyl Mixtures (Tranq), Naloxone Non-Reversal of Alpha-2 Agonist Effects, Necrotic Wound Syndrome, Overdose Management, and National Spread from Philadelphia (2023) REGULATORY · 2023
- OEHHA Proposition 65 List of Carcinogens or Reproductive Toxicants (CSV, list date 31-Jul-26) REGULATORY
- Permissible Exposure Limits – OSHA Annotated Table Z-1 REGULATORY
- EPA CompTox CTX API: predicted properties for DTXSID3040643 (Xylazine) REFERENCE
Same data as the API response, which is open and needs no key. The full per-record source list is available to authenticated callers.
Embed safety badge
<img src="https://api.aletheia.holisticquality.io/api/badge/hq-c-org-000187?context=human_adult&style=flat" alt="Xylazine safety badge">